Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

doi:10.5306/wjco.v10.i5.201

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5515)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

226

WORD

213

HTML

2378

Figures (1-1)

394

Tables (1-5)

215

Sum=3426

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

769

Download

1320

Sum=2089

May 24, 2019 (publication date) through Dec 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. May 24, 2019; 10(5): 201-212
Published online May 24, 2019. doi: 10.5306/wjco.v10.i5.201

Full Size Figure Download Figure

Figure 1 Kaplan-Meier survival curves survival among ovarian cancer patients. A: Progression free survival (PFS) in the whole cohort; B: PFS in the adjuvant and neoadjuvant groups; C: Overall survival (OS) in the whole cohort; D: OS in the adjuvant and neoadjuvant groups. PFS: Progression free survival; OS: Overall survival.

Citation: Meghal T, Dave V, Tang H, Kumar V, Xu Y. Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer. World J Clin Oncol 2019; 10(5): 201-212
URL: https://www.wjgnet.com/2218-4333/full/v10/i5/201.htm
DOI: https://dx.doi.org/10.5306/wjco.v10.i5.201